Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Paul J HengeveldJ Schilperoord-VermeulenM Y van der KliftJ M N DuboisP M KolijnF G KavelaarsM RijkenJ A DobberK NasserinejadS KerstingPeter E WesterweelArnon P KaterAnton W LangerakMark-David LevinPublished in: Blood cancer journal (2023)